27.45 +21.69 (82.44%)
COT
Stock Details
Last Trade:27.45 Change:+21.69 (82.44%) Prev Close:5.76 Open: 26.31 Days Range:25.00 – 29.98 52 Week Range: 0.59 - 6.80 Volume:443189 P/E: N/AEPS:0.00
View AllRecent Alerts 07/04/09
Recent Alert on 05/04/09 at 9:50am
Stifel Nicolaus Upgrades Cott (COT) to Buy
Stifel Nicolaus Upgrades Cott (COT) to Buy
Stifel Nicolaus upgrades Cott (NYSE: COT) from Hold to Buy with a $6 price target. This is the second upgrade for COT today. UBS also upgraded the stock to Buy this morning, with a $5 price target. Shares of COT are reacting positively to the... Read More
Recent Alert on 05/04/09 at 9:42am
Morning Movers 5/4: ACAD, CPSL, NAFC, LIZ, FREE, CYOU Higher; CCC, CPST Lower
Morning Movers 5/4: ACAD, CPSL, NAFC, LIZ, FREE, CYOU Higher; CCC, CPST Lower
Recent Alert on 05/01/09 at 12:57pm
Unusual 11 Mid-Day Movers 5/1: COT, TREE, FIG, WNC Higher; NVAX, COBR, BCRX, ALC Lower
Unusual 11 Mid-Day Movers 5/1: COT, TREE, FIG, WNC Higher; NVAX, COBR, BCRX, ALC Lower
Recent Alert on 05/01/09 at 10:39am
Morning Movers 5/1: COT, BGFV, TREE, BGC, ENTG, LQDT, NYNY Higher; COBR, RRI, SCOR, NANO, SGR Lower
Morning Movers 5/1: COT, BGFV, TREE, BGC, ENTG, LQDT, NYNY Higher; COBR, RRI, SCOR, NANO, SGR Lower
View AllRecent Press Releases
Press Release on 07/02/09 at 10:29am
Intravenous COTI-2 in Combination with Doxil(R) (Doxorubicin HCl) is More Effective Than Treatment with Doxil Alone in an Animal Model of Human Ovarian Cancer
Intravenous COTI-2 in Combination with Doxil(R) (Doxorubicin HCl) is More Effective Than Treatment with Doxil Alone in an Animal Model of Human Ovarian Cancer
Press Release on 07/02/09 at 10:29am
Intravenous COTI-2 in Combination with Doxil(R) (Doxorubicin HCl) is More Effective Than Treatment with Doxil Alone in an Animal Model of Human Ovarian Cancer
Intravenous COTI-2 in Combination with Doxil(R) (Doxorubicin HCl) is More Effective Than Treatment with Doxil Alone in an Animal Model of Human Ovarian Cancer
Press Release on 06/30/09 at 1:24pm
Inverness Medical Innovations - Concateno plc, Further Announcement Regarding UK Takeover Code Share Dealing Disclosure Requirements.
Inverness Medical Innovations - Concateno plc, Further Announcement Regarding UK Takeover Code Share Dealing Disclosure Requirements.
View AllRecent SEC Filings
No Recent SEC Filings Available